BRPI0922805A2 - método para prevenir ou reduzir a carcinogênese ou o estresse oxidativo - Google Patents

método para prevenir ou reduzir a carcinogênese ou o estresse oxidativo

Info

Publication number: BRPI0922805A2
Authority: BR; Brazil
Prior art keywords: prevent; oxidative stress; carcinogenesis; reduce; reduce carcinogenesis
Prior art date: 2008-12-05

Application number

BRPI0922805A

Other languages

English (en)

Inventor

Francesca Viti

Salvatore Bellinvia

Sergio Baroni

Original Assignee

Giuliani Int Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-05

Filing date

2009-12-03

Publication date

2015-12-22

2009-12-03 Application filed by Giuliani Int Ltd filed Critical Giuliani Int Ltd

2015-12-22 Publication of BRPI0922805A2 publication Critical patent/BRPI0922805A2/pt

2020-10-20 Publication of BRPI0922805B1 publication Critical patent/BRPI0922805B1/pt

2021-05-25 Publication of BRPI0922805B8 publication Critical patent/BRPI0922805B8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)

BRPI0922805A 2008-12-05 2009-12-03 uso de um composto químiopreventivo para a fabricação de um medicamento para tratar psoríase BRPI0922805B8 (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
EP08425775		2008-12-05
EP08425775.7		2008-12-05
US15767409P	2009-03-05	2009-03-05
US61/157,674		2009-03-05
US22228109P	2009-07-01	2009-07-01
US61/222,281		2009-07-01
PCT/EP2009/008631 WO2010063470A2 (en)	2008-12-05	2009-12-03	Methods for preventing or reducing carcinogenesis or oxidative stress

Publications (3)

Publication Number	Publication Date
BRPI0922805A2 true BRPI0922805A2 (pt)	2015-12-22
BRPI0922805B1 BRPI0922805B1 (pt)	2020-10-20
BRPI0922805B8 BRPI0922805B8 (pt)	2021-05-25

Family

ID=42232908

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0922805A BRPI0922805B8 (pt)	2008-12-05	2009-12-03	uso de um composto químiopreventivo para a fabricação de um medicamento para tratar psoríase
BRPI0922347A BRPI0922347A2 (pt)	2008-12-05	2009-12-03	métodos para prevenir ou reduzir carcinogênese de colón

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BRPI0922347A BRPI0922347A2 (pt)	2008-12-05	2009-12-03	métodos para prevenir ou reduzir carcinogênese de colón

Country Status (15)

Country	Link
US (3)	US8501806B2 (pt)
EP (2)	EP2355809A1 (pt)
JP (4)	JP2012510965A (pt)
KR (2)	KR20170042823A (pt)
CN (3)	CN102264361A (pt)
AU (2)	AU2009321724A1 (pt)
BR (2)	BRPI0922805B8 (pt)
CA (2)	CA2745224A1 (pt)
EA (1)	EA022314B1 (pt)
IL (1)	IL213334A (pt)
MX (2)	MX2011005869A (pt)
NZ (2)	NZ593560A (pt)
UA (1)	UA107562C2 (pt)
WO (2)	WO2010063470A2 (pt)
ZA (1)	ZA201104891B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRM20050390A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk)	2008-12-05	2015-01-26		Спосіб лікування псоріазу
US8754127B2 (en)	2009-02-16	2014-06-17	Nogra Pharma Limited	Alkylamido compounds and uses thereof
CN104254327A (zh)	2012-02-09	2014-12-31	诺格拉制药有限公司	治疗纤维化的方法
BR112014026160A2 (pt)	2012-04-18	2017-07-18	Nogra Pharma Ltd	métodos para tratar intolerância à lactose
CN105008394B (zh) *	2013-03-15	2021-10-22	诺格尔制药有限公司	治疗结肠直肠癌的方法
WO2017093444A1 (en) *	2015-12-01	2017-06-08	Nogra Pharma Limited	Compositions for oral administration in the treatment of inflammatory bowel disease
WO2019099457A1 (en) *	2017-11-14	2019-05-23	Quixgen, Inc.	Benzodioxinone compounds
UA129325C2 (uk)	2019-02-08	2025-03-19	Ногра Фарма Лімітед	Спосіб одержання 3-(4'-амінофеніл)-2-метоксипропіонової кислоти, її аналогів і проміжних сполук
KR102221365B1 (ko) *	2019-05-07	2021-03-02	(주)케어젠	트롤록스-펩타이드 결합체 및 그의 용도

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB767788A (en)	1953-12-28	1957-02-06	Schering Corp	Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en)	1961-09-29	1965-10-12	Merck & Co Inc	Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en)	1966-05-18	1969-05-13	Squibb & Sons Inc	O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en)	1972-02-25	1974-07-10	Merck & Co Inc	Preparation of pyrrylsalicylic acid
US4036951A (en)	1973-03-12	1977-07-19	Synergistics, Inc.	Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr)	1978-11-03	1980-05-30	Science Union & Cie	Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en)	1980-12-05	1982-09-07	Ppg Industries, Inc.	N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
EP0055689B1 (de)	1980-12-22	1984-07-04	Schering Aktiengesellschaft	In 3-Stellung substituierte 2,4,6-trihalogenierte Benzamide und deren Salze, deren Herstellung und Verwendung als Ersatzstoffe für natürliche Süssstoffe sowie Süssungsmittel auf Basis dieser Verbindungen
JPS58194814A (ja)	1982-05-11	1983-11-12	Nippon Shinyaku Co Ltd	免疫調節作用を有する薬剤
IL69282A (en)	1982-09-02	1988-06-30	Euro Celtique Sa	Method for the carboxylation of potassium phenoxide with carbon dioxide
EP0279096B1 (en)	1987-02-05	1993-07-07	Kureha Kagaku Kogyo Kabushiki Kaisha	Benzyl ether compound and process for producing the same
US4933330A (en)	1987-04-01	1990-06-12	Dak-Laboratoriet	Benzoic acid derivatives and use thereof
ATE113209T1 (de)	1988-05-05	1994-11-15	Tillotts Pharma Ag	Verwendung von 5-amino-salicylsäure für die behandlung von hautkrankheiten.
US5519014A (en)	1990-10-22	1996-05-21	Borody; Thomas J.	Treatment of non-inflammatory and non-infectious bowel disorders
DE69133348T3 (de)	1990-10-22	2011-05-12	Centre for Digestive Diseases Pty, Ltd.	Behandlung von nicht-entzündlichen darmerkrankungen
US5262549A (en)	1991-05-30	1993-11-16	Polaroid Corporation	Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en)	1992-01-21	1994-04-12	Ethyl Corporation	Profen resolution
EP0604641B1 (en) *	1992-06-30	2002-03-20	SHAPIRO, Howard, K.	Use of a combination containing an amine or amine-related derivative of benzoic acid and an amino-polysaccharide in the manufacture of a medicament for the treatment of inflammatory diseases
US5594151A (en)	1994-01-28	1997-01-14	Prolinx, Inc.	Phenylboronic acid complexing reagents derived from aminosalicylic acid
CA2190107A1 (en) *	1994-05-11	1995-11-23	Howard K. Shapiro	Compositions for treatment of chronic inflammatory diseases
US5594015A (en)	1994-06-22	1997-01-14	Regents Of The University Of California	Thiazolidine derivatives for the treatment of psoriasis
EP0817631A2 (en)	1995-03-28	1998-01-14	Janssen Pharmaceutica N.V.	Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
GB9600464D0 (en)	1996-01-09	1996-03-13	Smithkline Beecham Plc	Novel method
GB9617001D0 (en)	1996-08-13	1996-09-25	Tillotts Pharma Ag	Oral composition
DE19647582A1 (de)	1996-11-18	1998-05-20	Hoechst Ag	Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
WO1998043081A1 (en)	1997-03-26	1998-10-01	Ligand Pharmaceuticals Incorporated	Treatment of gastrointestinal disease with ppar modulators
AU8588798A (en)	1997-07-25	1999-02-16	Institut Pasteur	Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
AU9002798A (en)	1997-09-19	1999-04-12	Ono Pharmaceutical Co. Ltd.	Fused or nonfused benzene compounds
FR2773075B1 (fr)	1997-12-31	2000-05-05	Cird Galderma	Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en)	1998-11-11	2000-09-05	Moretti; Itagiba G.	Methods for treating inflammatory bowel disease
US6326364B1 (en)	1999-02-08	2001-12-04	Cedars-Sinai Medical Center	Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr)	1999-04-01	2001-05-11	Oreal	Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US20040034067A1 (en)	1999-04-15	2004-02-19	Macphee Colin Houston	Novel method of treatment
GB9908647D0 (en)	1999-04-15	1999-06-09	Smithkline Beecham Plc	Novel compounds
GB9914371D0 (en)	1999-06-18	1999-08-18	Smithkline Beecham Plc	Novel compounds
TWI262185B (en)	1999-10-01	2006-09-21	Eisai Co Ltd	Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
ES2226818T3 (es)	2000-04-19	2005-04-01	Neurotech Co., Ltd.	Compuestos, composiciones y metodos para prevenir la neurodegeneracion y daños cronicos en el sistema nervioso central.
DE60135742D1 (de)	2000-05-29	2008-10-23	Kyorin Seiyaku Kk	Substituierte phenylpropionsäure-derivate
US7049342B2 (en)	2000-05-29	2006-05-23	Kyorin Pharmaceutical Co., Ltd.	Substituted phenylpropionic acid derivatives
AU2001285311B2 (en)	2000-08-29	2005-09-15	Biocon, Ltd	Immunoregulatory compounds, derivatives thereof and their use
EP1348698A4 (en)	2000-12-05	2005-01-19	Kyorin Seiyaku Kk	SUBSTITUTED CARBOXYLENE DERIVATIVES
FR2822955B1 (fr)	2001-03-27	2003-10-03	Chru Lille	Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
CA2443935A1 (en)	2001-04-18	2002-10-31	Merck & Co., Inc.	Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
CA2354921A1 (en)	2001-05-24	2002-11-24	Yasuo Konishi	Drug evolution: drug design at hot spots
CA2463685A1 (en)	2001-10-16	2003-04-24	Dr. Reddy's Laboratories Ltd.	Novel .beta.-phenyl-.alpha.-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
GB0127916D0 (en)	2001-11-21	2002-01-16	Rowett Res Inst	Method
UA82835C2 (en)	2001-12-03	2008-05-26	Reddys Lab Ltd Dr	?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en)	2001-12-19	2003-06-19	Pfizer Inc.	Canine peroxisome proliferator activated receptor gamma
US20030220374A1 (en)	2002-01-14	2003-11-27	Pharmacia Corporation	Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en)	2002-04-12	2004-06-17	Wright Samuel D.	Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
GB0303609D0 (en)	2003-02-17	2003-03-19	Glaxo Group Ltd	Novel therapeutic method and compositions
US20060159648A1 (en) *	2003-02-17	2006-07-20	Davis Adrian F	Novel therapeutic method and compositions for topical administration
JPWO2004082715A1 (ja)	2003-03-20	2006-06-22	エーザイ株式会社	炎症性腸疾患治療剤としての併用医薬
AU2004261400A1 (en)	2003-07-21	2005-02-10	Laboratoires Serono Sa	Alkynyl aryl carboxamides
JP2007509180A (ja) *	2003-10-21	2007-04-12	インスパイアーファーマシューティカルズ，インコーポレイティド	疼痛を治療するための、非ヌクレオチド組成物および方法
WO2005040102A2 (en)	2003-10-28	2005-05-06	Dr. Reddy's Laboratories Ltd.	Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
JP2007513173A (ja) *	2003-12-03	2007-05-24	スミスクライン・ビーチャム・コーポレイション	ロシグリタゾンを用いる乾癬の治療
AU2004314731B2 (en) *	2004-01-20	2011-07-07	The Board Of Regents Of The University Of Oklahoma	Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en)	2004-03-04	2005-09-15	Arakis Ltd.	Derivatives of actarit and their therapeutic use
US20060286046A1 (en) *	2005-01-05	2006-12-21	Haber C Andrew	Skin care compositions
US20060270635A1 (en)	2005-05-27	2006-11-30	Wallace John L	Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it)	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) *	2005-07-22	2007-01-23	Giuliani Spa	Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de)	2005-12-22	2007-07-05	Saltigo Gmbh	Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en)	2006-02-23	2007-08-30	Lipid Nutrition B.V.	Immunoregulation
US7645801B2 (en)	2007-01-29	2010-01-12	Alaven Pharmaceutical Llc	Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) *	2007-02-28	2008-12-24	Giuliani Int Ltd	Ppar-gamma agonists stimulate enteric defensin expression
US20090054312A1 (en)	2007-08-22	2009-02-26	Wolf Dieter A	SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it)	2007-12-24	2009-06-25	Giuliani Int Ltd	Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en)	2008-03-31	2011-10-04	Saltigo Gmbh	Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk)	2008-12-05	2015-01-26		Спосіб лікування псоріазу
US8754127B2 (en)	2009-02-16	2014-06-17	Nogra Pharma Limited	Alkylamido compounds and uses thereof
EP2298321A1 (en)	2009-08-26	2011-03-23	Nordic Pharma	Novel pharmaceutical compositions for treating IBD
CA2841358A1 (en)	2011-07-15	2013-01-24	S.L.A. Pharma Ag	Pharmaceutical compositions for rectal administration
WO2013064153A1 (en)	2011-10-31	2013-05-10	Claus Selch Larsen	Prodrugs of non- steroid anti - inflammatory agents (nsaids)
CN104254327A (zh)	2012-02-09	2014-12-31	诺格拉制药有限公司	治疗纤维化的方法
BR112014026160A2 (pt)	2012-04-18	2017-07-18	Nogra Pharma Ltd	métodos para tratar intolerância à lactose
US9013997B2 (en)	2012-06-01	2015-04-21	Broadcom Corporation	System for performing distributed data cut-through
CN104619687A (zh)	2012-06-01	2015-05-13	诺格拉制药有限公司	能够调节t-细胞应答的双环杂环及其使用方法
JP2015528480A (ja)	2012-09-13	2015-09-28	ノグラファーマリミテッド	毛の成長の阻害方法
EP2895160B1 (en)	2012-09-13	2018-05-30	Nogra Pharma Limited	Methods of treating hair related conditions
WO2016154730A1 (en)	2015-04-02	2016-10-06	University Health Network	Gut anti-inflammatory agents for regulation of high blood glucose levels
KR102722949B1 (ko)	2015-06-15	2024-10-28	엔엠디 파마 에이/에스	신경근 장애의 치료에 사용하기 위한 화합물

2009
- 2009-03-12 UA UAA201108422A patent/UA107562C2/ru unknown
- 2009-12-03 EP EP09775102A patent/EP2355809A1/en not_active Withdrawn
- 2009-12-03 JP JP2011538898A patent/JP2012510965A/ja active Pending
- 2009-12-03 AU AU2009321724A patent/AU2009321724A1/en not_active Abandoned
- 2009-12-03 KR KR1020177009755A patent/KR20170042823A/ko not_active Ceased
- 2009-12-03 MX MX2011005869A patent/MX2011005869A/es active IP Right Grant
- 2009-12-03 AU AU2009321722A patent/AU2009321722B2/en not_active Ceased
- 2009-12-03 US US13/131,982 patent/US8501806B2/en not_active Expired - Fee Related
- 2009-12-03 WO PCT/EP2009/008631 patent/WO2010063470A2/en not_active Ceased
- 2009-12-03 EP EP09796299.7A patent/EP2355810B1/en not_active Not-in-force
- 2009-12-03 KR KR1020117015367A patent/KR101973209B1/ko not_active Expired - Fee Related
- 2009-12-03 CA CA2745224A patent/CA2745224A1/en not_active Abandoned
- 2009-12-03 WO PCT/EP2009/008633 patent/WO2010063472A1/en not_active Ceased
- 2009-12-03 NZ NZ593560A patent/NZ593560A/xx not_active IP Right Cessation
- 2009-12-03 CA CA2745415A patent/CA2745415C/en not_active Expired - Fee Related
- 2009-12-03 JP JP2011538896A patent/JP5674676B2/ja not_active Expired - Fee Related
- 2009-12-03 CN CN2009801525536A patent/CN102264361A/zh active Pending
- 2009-12-03 BR BRPI0922805A patent/BRPI0922805B8/pt not_active IP Right Cessation
- 2009-12-03 US US13/131,978 patent/US20110288058A1/en not_active Abandoned
- 2009-12-03 CN CN201710194543.5A patent/CN106955281A/zh active Pending
- 2009-12-03 CN CN2009801520208A patent/CN102264360A/zh active Pending
- 2009-12-03 EA EA201170754A patent/EA022314B1/ru not_active IP Right Cessation
- 2009-12-03 NZ NZ613418A patent/NZ613418A/en not_active IP Right Cessation
- 2009-12-03 MX MX2011005870A patent/MX2011005870A/es not_active Application Discontinuation
- 2009-12-03 BR BRPI0922347A patent/BRPI0922347A2/pt not_active IP Right Cessation
2011
- 2011-06-02 IL IL213334A patent/IL213334A/en active IP Right Grant
- 2011-07-04 ZA ZA2011/04891A patent/ZA201104891B/en unknown
2014
- 2014-05-29 JP JP2014110870A patent/JP5927236B2/ja not_active Expired - Fee Related
2015
- 2015-07-15 JP JP2015141003A patent/JP2015180702A/ja active Pending
2016
- 2016-04-01 US US15/088,654 patent/US9913817B2/en active Active

Also Published As

Publication number	Publication date
JP2014156485A (ja)	2014-08-28
EP2355809A1 (en)	2011-08-17
WO2010063470A2 (en)	2010-06-10
AU2009321722A1 (en)	2011-06-30
CN102264361A (zh)	2011-11-30
US20170056349A1 (en)	2017-03-02
AU2009321724A1 (en)	2011-07-14
IL213334A (en)	2015-10-29
EP2355810B1 (en)	2017-07-12
CA2745415C (en)	2017-01-10
BRPI0922805B8 (pt)	2021-05-25
US8501806B2 (en)	2013-08-06
CA2745415A1 (en)	2010-06-10
JP2015180702A (ja)	2015-10-15
KR20170042823A (ko)	2017-04-19
UA107562C2 (uk)	2015-01-26
EA022314B1 (ru)	2015-12-30
IL213334A0 (en)	2011-07-31
JP5927236B2 (ja)	2016-06-01
JP2012510963A (ja)	2012-05-17
US20110288177A1 (en)	2011-11-24
KR20110091585A (ko)	2011-08-11
MX2011005869A (es)	2011-06-27
US20110288058A1 (en)	2011-11-24
NZ613418A (en)	2015-01-30
EA201170754A1 (ru)	2011-12-30
BRPI0922805B1 (pt)	2020-10-20
WO2010063472A1 (en)	2010-06-10
CA2745224A1 (en)	2010-06-10
WO2010063470A3 (en)	2010-08-05
MX2011005870A (es)	2011-06-30
NZ593560A (en)	2013-08-30
JP5674676B2 (ja)	2015-02-25
BRPI0922347A2 (pt)	2018-03-20
AU2009321722B2 (en)	2015-10-22
JP2012510965A (ja)	2012-05-17
KR101973209B1 (ko)	2019-04-26
ZA201104891B (en)	2014-12-23
EP2355810A2 (en)	2011-08-17
WO2010063470A9 (en)	2010-10-07
CN106955281A (zh)	2017-07-18
US9913817B2 (en)	2018-03-13
CN102264360A (zh)	2011-11-30

Publication	Publication Date	Title
BRPI0922805A2 (pt)	2015-12-22	método para prevenir ou reduzir a carcinogênese ou o estresse oxidativo
BRPI0817547A2 (pt)	2015-03-31	Método para realizar pirólise
DK2299862T3 (da)	2017-11-27	Sål til en sko, i særdeleshed til en løbesko
DK2252380T3 (da)	2013-01-28	Skateboard
FR2932963B1 (fr)	2010-08-27	Chaussure a semelage ameliore
FR2940019B1 (fr)	2011-03-25	Chaussure a semelage ameliore
EP2240688A4 (en)	2014-01-22	FLUID ROTOR
EP2326553A4 (en)	2013-02-13	TRIM FLAP
BRPI0907651A2 (pt)	2015-07-21	Acessório para calçados
BRPI0913186A2 (pt)	2016-01-12	acionamento manual para o acionamento gradual
DOS2008000078S (es)	2009-05-31	Dispositivos para aplicar betun al calzado
BRPI0922098A2 (pt)	2015-12-15	composto inorgânicos
BRPI0921679A2 (pt)	2016-02-16	composto útil para tratar celulite
BRPI0917718A2 (pt)	2016-05-31	calçado
BRPI0905660A2 (pt)	2015-07-07	"método para reduzir ou inibir a angiogênese"
BRPI0917655A8 (pt)	2016-07-12	sobremesa composta e processo para preparar a mesma.
EP2256308A4 (en)	2011-06-08	PLAY COMPENSATION ELEMENT
BRPI0822797A2 (pt)	2015-06-30	Transmissão para uma máquina mecânica, e, máquina mecânica
BRPI0912435A2 (pt)	2016-10-04	processo melhorado para telomerizar butadieno
ES1069811Y (es)	2009-08-26	Apero manual
DK2359029T3 (da)	2013-02-11	Gear
IT1391542B1 (it)	2012-01-11	Cassaforte
ES1067680Y (es)	2008-09-01	Faja para adelgazar
DK2191995T3 (da)	2013-01-02	Gear
FI20085370L (fi)	2009-10-26	Pituusleikkuri

Legal Events

Date	Code	Title	Description
2017-11-07	B25D	Requested change of name of applicant approved	Owner name: NOGRA PHARMA LIMITED (IE)
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-12-24	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-05-26	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-10-20	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-09-27	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 13A ANUIDADE.
2023-01-17	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.